Actinium Pharmaceuticals (NYSE:ATNM) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

Other analysts have also recently issued research reports about the company. B. Riley cut Actinium Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Maxim Group decreased their price objective on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright cut their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $11.40.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $1.80 on Wednesday. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24. The company has a fifty day moving average of $3.69. The firm has a market cap of $53.61 million, a price-to-earnings ratio of -1.05 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Equities research analysts anticipate that Actinium Pharmaceuticals will post -1.38 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATNM. Rhumbline Advisers boosted its position in Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares during the last quarter. Sanders Morris Harris LLC purchased a new position in Actinium Pharmaceuticals in the first quarter valued at about $78,000. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the 2nd quarter valued at approximately $92,000. Bank of New York Mellon Corp increased its holdings in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at approximately $142,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.